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Introduction: We aimed to investigate several blood-based biomarkers related
to inflammation, immunity, and stress response in a cohort of patients without
stroke-associated infections regarding their predictive abilities for functional outcome and
explore whether they correlate with MRI markers, such as infarct size or location.
Methods: We combined the clinical and radiological data of patients participating in two
observational acute stroke cohorts: the PREDICT and 1000Plus studies. The following
blood-based biomarkers were measured in these patients: monocytic HLA-DR, IL-6,
IL-8, IL-10, LBP, MRproANP, MRproADM, CTproET, Copeptin, and PCT. Multiparametric
stroke MRI was performed including T2∗, DWI, FLAIR, TOF-MRA, and perfusion imaging.
Standard descriptive sum statistics were used to describe the sample. Associations
were analyzed using Fischer’s exact test, independent samples t-test and Spearmans
correlation, where appropriate.
Results: Demographics and stroke characteristics were as follows: 94 patients without
infections, mean age 68 years (SD 10.5), 32.2% of subjects were female, median
NIHSS score at admission 3 (IQR 2–5), median mRS 3 months after stroke 1 (IQR 0–2),
mean volume of DWI lesion at admission 5.7ml (SD 12.8), mean FLAIR final infarct
volume 10ml (SD 14.9), cortical affection in 61% of infarctions. Acute DWI lesion volume
on admission MRI was moderately correlated to admission/maximum IL-6 as well as
maximum LBP. Extent of perfusion deficit and mismatch were moderately correlated to
admission/maximum IL-6 levels. Final lesion volume on FLAIR was moderately correlated
to admission IL-6 levels.
Conclusion: We found IL-6 to be associated with several parameters from acute stroke
MRI (acute DWI lesion, perfusion deficit, final infarct size, and affection of cortex) in a
cohort of patients not influenced by infections.
Clinical Trial Registration: www.ClinicalTrials.gov, identifiers NCT01079728 and
NCT00715533
Keywords: stroke, biomarker, MRI, IL-6, neuroinflammation
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INTRODUCTION
Stroke is globally recognized as a leading cause for mortality and
adult disability. While the advent of intravenous thrombolysis
and recanalization has significantly improved the outcome of
stroke, a significant proportion of patients persist to suffer
from deficits and disabilities. This is partly explained by the
course of stroke itself, but also depending on neurological
and medical complications (1–3). Prognosis and precise
prediction of outcome remains challenging, especially during
the hyperacute phase of the disease. While demographic and
clinical characteristics, such as i.e., age and severity of acute
clinical syndrome, allow for an educated guess (4), the accuracy
of prediction is limited (5). For the post-acute phase of the
disease, recent progress has been made in prediction of motor
and cognitive recovery (6, 7).
Development of more accurate scores to predict outcome in
the acute setting may benefit from the inclusion of biomarkers.
While individual association of sanguine parameters with stroke
characteristics and functional outcome has been reported, no
single biomarker stands out in the field. Immune parameters
including cytokines and other acute phase proteins are indicative
FIGURE 1 | Timeline of the two studies supporting this analysis (A) and study flow chart (B).
to the risk of post-stroke infections but have also been associated
to functional outcome after stroke (8).
We aimed to investigate a range of inflammation-, immunity-,
and stress-related biomarkers in a cohort of patients without
stroke-associated infections regarding their predictive abilities
for functional outcome and explore whether they correlate with
MRI markers, such as infarct size or location.
METHODS
We combined the clinical and radiological data of patients
participating in two observational acute stroke cohorts: the
PREDICT and 1000Plus studies (clinicaltrials.gov NCT01079728
and NCT00715533). Both studies received full approval by the
institutional ethics’ committee, including the pooling of data
for combined analysis. All patients (or if necessary, their legal
representatives) gave informed consent to participation. Protocol
details of both studies have been previously published (9, 10).
Briefly, both studies recruited acute ischemic stroke patients to
investigate either the prediction of stroke-associated pneumonia
(PREDICT) or the natural course of multimodal MRI parameters
(1000Plus), especially the evolution of DWI-perfusion imaging-
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mismatch. There was significant overlap of visit time points
throughout the course of the study (see Figure 1). PREDICT
was a multicentric study, with one of the participating centers
(Charité Campus Benjamin Franklin) being the only study
site in the 1000Plus study. PREDICT recruited 189 patients
on that common site, 94 of which also participating in
the 1000Plus study. We excluded patients suffering from
an infection during their time of hospital admission for
this analysis.
Blood samples parameters were obtained within the first 4
days of hospital admission. Samples were immediately post-
processed and then frozen at −80◦C in order to allow for batch
analyses at the end of the study. Serum levels of mid-regional
pro atrial natriuretic peptide (MRproANP), mid-regional pro
adrenomedullin (MRproADM), C-terminal pro endothelin
(CTproET), ultrasensitive copeptin (CPus), and ultrasensitive
procalcitonin (PCTus) were measured using fluorescent
immunoassays on the automated BRAHMS KRYPTOR compact
PLUSTM analyzer (BRAHMS GmbH/Thermo Fisher Scientific,
Henningsdorf, Germany) according to the manufacturer’s
protocol. The lower limits of quantitation were 4.5 pmol/l
for MRproANP, 0.05 nmol/l for MRproADM, 3 pmol/l for
CTproET, 1.9 pmol/l for CPus, and 0,02 µg/l for PCTus. Plasma
concentrations of IL-6, IL-8, IL-10, and LBP were determined
with the IMMULITETM semi-automatic chemiluminescent
immunoassay (Siemens Medical Solutions, Bad Nauheim,
Germany). The detection limit for IL-6 and IL-8 is 2,
1 pg/ml for IL-10 and 0.8µg/ml for LBP. Expression of
human leukocyte antigen-DR (HLA-DR) on monocytes was
determined in EDTA whole blood samples by flow cytometry
using a highly standardized quantitative assay, as described
earlier (9).
Multiparametric stroke MRI was performed on a 3T
scanner (Tim Trio; Siemens AG, Erlangen, Germany) at
admission (always within 24 h of the event), the following
day and lastly 4–6 days after the event. Applied sequences
contained T2∗, DWI, FLAIR, TOF-MRA, and for the first
two imaging time points also perfusion imaging. For further
detail please refer to the published protocol (10). Admission
MRI was performed as initial imaging upon presentation, or
if outside of regular hours as the first examination the next
morning. Follow-up MRIs were performed in the morning
of the respective days. Blood samples were collected for
the first day as soon as the patients and/or their legal
representatives consented. The following samples were drawn
with the routine laboratory rounds in the morning. Hence,
delay between imaging and blood sampling was kept as short as
logistically possible.
Standard descriptive sum statistics were used to describe
demographics and stroke characteristics as well as biomarker and
imaging results. Associations were analyzed by use of Fischer’s
exact test, independent samples t-test and Spearmans correlation,
depending on character of variables. Alpha-error level was set
at 2-tailed p = 0.05. All statistics were performed using SPSS
(version 24.0, IBM, Armonk, NY, USA). In view of the small
sample size and the explorative nature of the study, we decided
against statistical correction such as Bonferroni.
RESULTS
We identified 94 patients participating in both Predict and
1000Plus. Three of them suffered from an infection during the
course of their hospital stay and were excluded from this analysis
(see Figure 1B for further detail). Mean age was 68 years (SD
10.5) and 32.2% of subjects were female. Median NIHSS score
at admission was 3 (IQR 2–5). At 3 months, median mRS was
1 (IQR 0–2). Thrombolysis was applied in 23% of patients. For
further details on clinical syndrome on admission, risk factors
and stroke etiology refer to Table 1.
Initial MRI was performed at a median of 549.5min (IQR
130.25–860) after event. Mean volume of DWI lesion at
admission was 5.7ml (SD 12.8), mean final infarct volume as
measured on FLAIR was 10ml (SD 14.9). The right hemisphere
was more frequently affected than the left hemisphere (52 vs.
37%) and cortex was involved in 61% of infarctions. Blood
samples were collected during the first 4 days of hospitalization
after stroke, and values for day of admission as well as
maximum/minimum values are outlined in Table 2.
Age of patients was associated with IL-6, MRproANP,
MRproADM, and CTproET. Stroke severity at admission
as measured by National Institute of Health Stroke Scale
TABLE 1 | Demographics and clinical stroke characteristics.
n 91
Sex, n (%) female 29 (32.2)
Age, years, mean (SD) 68.0 (10.5)
Admission NIHSS, median (IQR) 3 (2-5)
Admission mRS, median (IQR) 2 (1-3)
ADMISSION SYMPTOMS
Aphasia [7] 10 (11.9)
Motor deficit 67 (77.9)
Dysarthria [7] 46 (54.8)
Dysphagia [11] 5 (6.3)
RISK FACTORS
Diabetes mellitus 25 (28.7)
Atrial fibrillation 14 (16.1)
Previous stroke 16 (18.4)
Arterial hypertension 74 (85.1)
Hyperlipidemia 55 (63.2)
Smoking [61] 5 (16.1)
Thrombolysis 20 (23.0)
TOAST
Large artery occlusion 56 (64.4)
Cardioembolism 18 (20.7)
Small artery disease 6 (6.9)
Other etiology 3 (3.4)
Unknown etiology 3 (3.4)
Concurring etiology 1 (1.1)
mRS 90 days after event, median (IQR) [17] 1 (0–2)
Values given are n (%) if not explicitly stated otherwise, missing cases reported if >5 as
[n]. NIHSS, National Institute of Health Stroke Scale; mRS, modified Rankin Scale; TOAST,
Trial of Org10172 in Acute Stroke Treatment.
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TABLE 2 | Imaging and blood-based biomarker results.




DWI lesion volume on acute MRI, ml 5.7 (12.8)
PI deficit volume on acute MRI, ml 45.1 (78.0)
DWI-PI mismatch on acute MRI, ml 26.4 (58.5)
TYPE OF INFARCTION
Territorial 76 (85.4)
Lacunar infarction 12 (13.5)
Borderzone infarction 1 (1.1)
REGIONS AFFECTED
Any Cortex 54 (60.7)
Caudate 3 (3.3)
Lenticulate 4 (4.4)
Capsula interna 8 (8.8)
Insula 11 (12.1)
ASPECT M1 6 (6.6)
ASPECT M2 17 (18.7)
ASPECT M3 14 (15.4)
ASPECT M4 15 (16.5)
ASPECT M5 34 (37.4)
ASPECT M6 21 (23.1)
FLAIR lesion volume on Follow Up, ml [33] 10.0 (14.9)
HLA-DR, EPITOPES/CELL, MEDIAN (IQR)
At inclusion [3] 18,387 (14,434–25,788)
Lowest [1] 16,505 (11,386–21,285)
IL-6, PG/ML, MEDIAN (IQR)
At inclusion [3] 2.8 (2.0–5.2)
Highest [1] 5.2 (2.7–11.0)
IL-8, PG/ML, MEDIAN (IQR)
At inclusion [3] 5.0 (5.0–5.0)
Highest [1] 5.0 (5.0–5.2)
IL-10, PG/ML, MEDIAN (IQR)
At inclusion [3] 5.0 (5.0–5.0)
Highest [1] 5.0 (5.0–5.0)
LBP, µG/ML, MEDIAN (IQR)
At inclusion [3] 7.23 (5.48–9.34)
Highest [1] 8.90 (6.68–11.65)
MPproANP, PG/ML, MEDIAN (IQR)
At inclusion [29] 111.4 (65.5–180.9)
Highest [23] 122.5 (79.1–195.8)
MPproADM, PG/ML, MEDIAN (IQR)
At inclusion [29] 0.703 (0.593–0.868)
Highest [22] 0.751 (0.613–0.917)
CTproET, PG/ML, MEDIAN (IQR)
At inclusion [30] 61.4 (50.7–75.9)
Highest [22] 64.4 (54.6–83.1)
CPus, PG/ML, MEDIAN (IQR)
At inclusion [29] 8.84 (5.27–14.22)
Highest [22] 10.19 (5.60–17.40)
PCT us, PG/ML, MEDIAN (IQR)
At inclusion [30] 0.031 (0.024–0.041)
Highest [23] 0.039 (0.028–0.050)
Values given are n (%) if not explicitly stated otherwise, missing cases reported if >5 as
[n]. HLA-DR, Human leukocyte antigen expression on monocytes; IL-6, IL-8, IL-10, three
interleukins; LBP, lipopolysaccharide-binding protein; MRproANP, mid-regional pro atrial
natriuretic peptide; MRproADM, mid-regional pro adrenomedullin; CTproET, C-terminal
pro endothelin; CPus, ultrasensitive copeptin; PCTus, ultrasensitive procalcitonin.
(NIHSS) score was associated with IL-6. Functional outcome
as measured by modified Rankin Scale (mRS) at day 90 was
associated with admission levels of ultrasensitive Copeptin,
maximum MRproADM, IL-6, and minimum HLA-DR
levels (Table 3).
Acute volume of DWI restriction on admission MRI scans
was moderately correlated to admission (Spearman’s ρ 0.336)
and maximum (Spearman’s ρ 0.276) IL-6 as well as maximum
LBP (Spearman’s ρ 0.222) levels. Extent of perfusion imaging
(PI) deficit and DWI-PI-Mismatch were moderately correlated
to admission (Spearman’s ρ 0.306 and 0.231, respectively) and
maximum (Spearman’s ρ 0.277 and 0.215, respectively) IL-6
levels. Final lesion volume on FLAIR was moderately correlated
to admission IL-6 levels (Spearman’s ρ 0.364) (Table 4).
Cortical infarcts were associated with higher IL-6 levels at
admission. By use of the ASPECT scoring system we only found
inconsistent associations of biomarker levels with infarct location
(Supplementary Table 1).
DISCUSSION
We examined the relationship of inflammatory, immune, and
stress biomarkers with MRI parameters in 91 stroke patients
not suffering from stroke-associated infections during the course
of the study. Interleukin-6 was associated with infarct size and
tissue at risk, as well as final infarct volume. The other studied
biomarkers did not show any associations with imaging markers
in the absence of infection. Overall, the studied cohort was rather
mildly affected by stroke (median admission NIHSS 3 IQR 2–5
and 3 months mRS 1 IQR 0–2).
The biological role of IL-6 in ischemic stroke remains
uncertain. Astrocytes and microglia express IL-6, but whether
it primarily exerts neurotoxic or—protective effects is a matter
of scientific discourse (11, 12). Our study found a significant
association of IL-6 levels with NIHSS scores at admission,
although Spearman’s ρ only showed moderate correlation.
Furthermore, we found a significant correlation of IL-6 levels
with lesion volume, whether on DWI scans at admission,
PI deficit, DWI-PI mismatch or on follow-up FLAIR images,
which is in line with the association of IL-6 levels and
NIHSS scores at admission. Infarct size has previously been
reported to correlate at least with intrathecal levels, but not
consistently with serum levels, of IL-6 (13–15). IL-6 was
repeatedly associated with poor functional outcome, but whether
this is an independent effect or a signal due to infection
remains unclear (8). Our data shows a significant association
of IL-6 with functional outcome as measured by mRS in
a cohort of patients not suffering from infection, further
corroborating an association independent of infections. IL-
6 has been previously linked to small vessel disease and
silent cerebral infarctions (16–18). IL-6 and also IL-10 were
associated with the presence of diffusion-perfusion- or clinical-
diffusion-mismatch on acute stroke MRI (19–21). Furthermore,
cortical infarcts were associated with IL-6. The associations
of several other biomarkers with localization of lesions have
to be interpreted with caution considering the sample size
and plausibility.
Frontiers in Neurology | www.frontiersin.org 4 February 2019 | Volume 10 | Article 83
Hotter et al. IL-6 Correlates With Stroke Size
TABLE 3 | Association of biomarkers at inclusion and lowest/highest measurement with clinical parameters.
Aphasia Motor deficit Dysarthria Dysphagia Sex NIHSS mRS d90 Age
HLA-DR Inclusion 0.405 0.979 0.548 0.757 0.606 0.409 0.052 0.249
Lowest 0.987 0.436 0.959 0.173 0.340 0.099 0.030 0.069
IL-6 Inclusion 0.410 0.478 0.912 0.739 0.824 0.005 0.252 0.001
Highest 0.369 0.281 0.983 0.438 0.884 0.005 0.015 0.030
IL-8 Inclusion 0.443 0.050 0.640 0.552 0.803 0.073 0.226 0.339
Highest 0.633 0.393 0.386 0.467 0.597 0.331 0.683 0.566
IL-10 Inclusion 0.416 0.468 0.136 0.611 0.564 0.916 0.248 0.460
Highest 0.247 0.360 0.257 0.727 0.989 0.683 0.587 0.236
LBP Inclusion 0.086 0.364 0.958 0.660 0.227 0.291 0.952 0.148
Highest 0.857 0.861 0.442 0.353 0.621 0.062 0.637 0.152
MPproANP Inclusion 0.486 0.640 0.012 0.029 0.914 0.163 0.654 0.005
Highest 0.521 0.287 0.047 0.005 0.926 0.068 0.911 0.005
MPproADM Inclusion 0.001 0.320 0.310 0.915 0.296 0.241 0.264 <0.001
Highest 0.351 0.209 0.618 0.979 0.547 0.158 0.043 0.001
CTproET Inclusion 0.398 0.323 0.613 0.994 0.962 0.160 0.344 0.018
Highest 0.015 0.330 0.893 0.888 0.933 0.092 0.169 0.039
Copeptin us Inclusion 0.720 0.455 0.548 0.436 0.357 0.768 0.006 0.540
Highest 0.335 0.910 0.354 0.441 0.115 0.918 0.144 0.298
PCT us Inclusion 0.643 0.381 0.007 0.736 0.286 0.254 0.962 0.975
Highest 0.855 0.560 0.056 0.908 0.362 0.634 0.230 0.711
Values given are two-sided p-values obtained by a students’ t-test; Bold text denotes significant associations; HLA-DR, Human leukocyte antigen expression on monocytes; IL-6,
IL-8, IL-10, three interleukins; LBP, lipopolysaccharide-binding protein; MRproANP, mid-regional pro atrial natriuretic peptide; MRproADM, mid-regional pro adrenomedullin; CTproET,
C-terminal pro endothelin; CPus, ultrasensitive copeptin; PCTus, ultrasensitive procalcitonin.
Interestingly, in our cohort of patients not suffering from
infections, plasma levels of IL-8 and IL-10 were mostly not
detectable and below the upper limit of normal (5.0 pg/ml).
This is in line with previous findings by us and Chamorro et al.
showing increased IL-10 levels in patients with stroke-associated
infections (22, 23). These cytokines may therefore be mainly
triggered by systemic inflammation in the course of infectious
complications after stroke, whereas neuroinflammation within
the CNS does not seem to trigger their expression.
As previously described, we found functional outcome
after 3 months to be inversely correlated to HLA-DR (24),
and furthermore correlated to MRproADM and ultrasensitive
Copeptin. Expression of monocytic HLA-DR is a marker of
monocyte activation and has been shown to be a key marker
for stroke-induced immune depression (9, 25). Lower HLA-DR
expression is a strong predictor of stroke-associated pneumonia
and is associated with worse functional outcome (9, 24). The
latter association is further corroborated in our data independent
of infection.
Several biomarkers showed an association with age, and
while this has previously been reported for CTproET (26) and
appears plausible for a vascular stress marker as MRproANP,
the relationship for MRproADM and IL-6 is less seemingly
obvious. LBP is a marker of bacterial translocation and higher
levels are found in patients with post-stroke infection (27).
It is also associated with a worse short-term stroke outcome
(28). We could not reproduce this finding in stroke patients
not suffering from infection or show any association with
imaging characteristics. MRproANP is used as a biomarker
for hemodynamic stress and was previously shown to indicate
higher risk for ischemic stroke (29). There were no significant
associations with imaging characteristics or functional outcome
in our cohort. MRproADM exerts vasodilating, vasoprotective,
and angiogenic effects and is associated with post-stroke
infections (30) and functional outcome after stroke (31).
MRproADM has been associated with progression of small
vessel disease accompanying cognitive decline (32). We could
not reproduce the association with poor outcome or find
an association with imaging characteristics. The vasopressin
surrogate CP has been associated with higher risk of all-
cause mortality, poor functional outcome and infections after
ischemic stroke (33–36). Furthermore, it has been proposed to
improve prediction of recurring cerebrovascular events (37).
CTproET is influenced by age, renal function, and hemodynamic
parameters of healthy subjects, and is a strong vasoconstrictor
(26). While it has not been studied as biomarker in ischemic
stroke before, its derivative endothelin has been associated with
carotid atherosclerosis and silent cerebral infarctions (38). Both
biomarkers were not associated with outcome in our cohort,
and did not show any significant correlations with imaging
findings. PCT is a blood-based marker for infection in general
and was shown to be associated with post-stroke infections and
functional outcome (36, 39, 40). Furthermore, higher levels of
PCT are associated with extent of small vessel disease and silent
infarctions on MRI (41). Our data did not show an association
with functional outcome or imaging characteristics.
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TABLE 4 | Association of biomarkers at inclusion and lowest/highest measurement with imaging parameters.
Initial DWI volume Initial PI deficit Initial mismatch Final FLAIR volume
HLA-DR At Inclusion 0.933 0.936 0.716 0.397
Lowest 0.678 0.234 0.443 0.300
IL-6 At Inclusion 0.002 0.016 0.030 0.006
Highest 0.009 0.029 0.042 0.383
IL-8 At Inclusion 0.955 0.667 0.928 0.068
Highest 0.787 0.798 0.099 0.347
IL-10 At Inclusion 0.290 0.555 0.701 0.822
Highest 0.081 0.101 0.595 0.435
LBP At Inclusion 0.084 0.877 0.625 0.546
Highest 0.037 0.349 0.431 0.688
MPproANP At Inclusion 0.949 0.945 0.566 0.830
Highest 0.853 0.795 0.486 0.941
MPproADM At Inclusion 0.882 0.901 0.123 0.130
Highest 0.682 0.801 0.267 0.340
CTproET At Inclusion 0.923 0.887 0.665 0.827
Highest 0.834 0.906 0.541 0.849
Copeptin us At Inclusion 0.144 0.801 0.457 0.701
Highest 0.487 0.673 0.648 0.815
PCT us At Inclusion 0.804 0.214 0.224 0.637
Highest 0.418 0.151 0.381 0.513
Values given are two-sided p-values obtained by a Spearman’s correlation; Bold text denotes significant associations; HLA-DR, Human leukocyte antigen expression on monocytes; IL-6,
IL-8, IL-10, three interleukins; LBP, lipopolysaccharide-binding protein; MRproANP, mid-regional pro atrial natriuretic peptide; MRproADM, mid-regional pro adrenomedullin; CTproET,
C-terminal pro endothelin; CPus, ultrasensitive copeptin; PCTus, ultrasensitive procalcitonin.
Our study suffers from several limitations: the sample
size, while average for a study in this field, is limited,
especially considering the amount of analyses performed.
While multiple testing was a concern for us, the purpose
of this study was purely exploratory. Our findings need to
be corroborated by further confirmatory studies. Furthermore,
our study cohort was overall rather mildly affected by
stroke, not necessarily reflecting a cohort of severely impaired
patients. Strengths of this report are the prospective collection
of data with an in-depth clinical and neuroradiological
assessment during the acute course of the disease avoiding
recall H bias.
Our data supports the conclusion that IL-6 is an inflammatory
marker of cerebral parenchymal damage independent of
systemic infections.
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